Network Insights Methodology Get Access

Sanofi

ORG Health Care / Pharmaceuticals Momentum 9.2ML Momentum Score (0-100). Weighted composite of 9 features: mention velocity, article breadth, relationship density, deal context, recency, market cap, enrichment completeness, mention concentration, entity type. NORMALPSI regime classification. QUIET (<0.3): baseline activity. NORMAL (0.3-0.5): typical deal flow. ELEVATED (0.5-0.7): above-average signals. HIGH (0.7-0.85): significant activity. EXTREME (>0.85): exceptional signal concentration. Primary: Spectral Shift

$63B revenue (2024), Paris-based Sanofi manufactures vaccines, rare disease therapies, and oncology treatments across 100+ countries. Increasingly active in digital health and AI partnerships to enhance precision medicine capabilities.

Strategic involvement in AI-driven healthcare innovation; referenced in context of Waiv spinout from Owkin ($33M Series A for AI-powered cancer diagnostics)
-0.50
PSI ScorePlocamium Signal Index - composite z-score from 5 orthogonal signals: news frequency, targeted sentiment, graph centrality, regulatory filings, and clinical trial activity.
9.2
MomentumML Momentum Score (0-100). Weighted composite of 9 features including mention velocity, article breadth, deal context, and relationship density. Retrained weekly.
1%
ConfidenceSignal confidence - percentage of PSI sub-signals with sufficient data (30+ observations). Higher confidence means the PSI score is based on more complete data.
8
ConnectionsDegree centrality - number of unique entities this entity co-occurs with in news signals and articles. Higher = more connected in the intelligence network.
Connected Entities
FDA Europe Merck California AstraZeneca Paris CEO Novo Nordisk
Watch This Entity
PSI Intelligence
30-Day Trend
2026-04-28 2026-05-28 8 0 Degree Mentions
Signal Decomposition
Attention Cascade
3.333
Narrative Drift
0.000
Spectral Shift
1184.899
Sentiment-Momentum Divergence
0.000
Source Concentration
0.563
Peer Comparison
Not yet ranked. Sector-relative scoring requires at least four entities in the same BICS sector with PSI history; this entity does not yet meet the threshold or sits in a sector with insufficient peers.
Network Analysis
8 Degree Centrality
Ego Network (top connections)
FDA (weight 12.0)Europe (weight 5.0)Merck (weight 5.0)California (weight 3.0)AstraZeneca (weight 3.0)Paris (weight 2.0)CEO (weight 2.0)Novo Nordisk (weight 1.0) FDAEuropeMerckCaliforniaAstraZenecaParisCEONovo Nordisk Sanofi (degree 8) Sanofi
Centrality History
2026-04-28 2026-05-28 8 0 Degree Mentions
EntityWeight StatusFirst Seen
FDA 12 NEW
Europe 5 NEW
Merck 5 NEW
California 3 NEW
AstraZeneca 3 NEW
Paris 2 NEW
CEO 2 NEW
Novo Nordisk 1 NEW
Article Coverage (20)
DateLaneTitle
2026-05-28 Healthcare M&A Apogee Secures $1.3 Billion From Blackstone as Alternative Capital Reshapes Biotech Financing
2026-04-23 Healthcare M&A Pharma Giants Capitulate as Trump Wins Initial Pricing Concessions, Signals Escalation Ahead
2026-03-28 Healthcare M&A A Week of Bolt-On Deals; Wave Crashes on Obesity Data; Sanofi Partners With TCE Startup; and More
2026-03-28 Healthcare M&A CHMP Recommends Subcutaneous Form of Sanofi's Sarclisa and Four New Drugs
2026-03-28 Healthcare M&A CHMP Recommends Subcutaneous Form of Sanofi's Sarclisa and Four New Drugs
2026-03-28 Healthcare M&A CHMP Recommends Subcutaneous Form of Sanofi's Sarclisa and Four New Drugs
2026-03-28 Healthcare M&A CHMP Recommends Subcutaneous Form of Sanofi's Sarclisa and Four New Drugs
2026-03-28 Healthcare M&A CHMP Recommends Subcutaneous Form of Sanofi's Sarclisa and Four New Drugs
2026-03-28 Healthcare M&A CHMP Recommends Subcutaneous Form of Sanofi's Sarclisa and Four New Drugs
2026-03-28 Healthcare M&A CHMP Recommends Subcutaneous Form of Sanofi's Sarclisa and Four New Drugs
2026-03-28 Healthcare M&A CHMP Recommends Subcutaneous Form of Sanofi's Sarclisa and Four New Drugs
2026-03-28 Healthcare M&A CHMP Recommends Subcutaneous Form of Sanofi's Sarclisa and Four New Drugs
2026-03-28 Healthcare M&A CHMP Recommends Subcutaneous Form of Sanofi's Sarclisa and Four New Drugs
2026-03-23 Healthcare M&A Sanofi Extends $180M to California T Cell Engager Startup Kali
2026-03-23 Healthcare M&A Sanofi Extends $180M to California T Cell Engager Startup Kali
2026-03-23 Healthcare M&A Sanofi Extends $180M to California T Cell Engager Startup Kali
2026-03-23 Healthcare M&A Sanofi Extends $180M to California T Cell Engager Startup Kali
2026-03-23 Healthcare M&A Sanofi Extends $180M to California T Cell Engager Startup Kali
2026-03-23 Healthcare M&A Sanofi Extends $180M to California T Cell Engager Startup Kali
2026-03-23 Healthcare M&A Sanofi Extends $180M to California T Cell Engager Startup Kali

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-05-28 ← Intelligence Network